Lantern Pharma Inc.
LTRN evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $13.9M
- Lead Asset:
- lp-100 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for LTRN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LTRN
Lantern Pharma Inc. (LTRN) is a clinical-stage, AI-native biopharmaceutical company developing precision oncology therapies using artificial intelligence and genomic data, with a pipeline including Phase 2 and Phase 1/2 candidates and a wholly owned AI subsidiary.
Key risk: Cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$13.9M
Cash Runway
—
Lead Asset
lp-100 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for Lantern Pharma Inc..
Lantern Pharma Inc. (LTRN) is a clinical-stage, AI-native biopharmaceutical company developing precision oncology therapies using artificial intelligence and genomic data, with a pipeline including Phase 2 and Phase 1/2 candidates and a wholly owned AI subsidiary.
- Cash and equivalents of $6.7M as of 2026-06-30 [sec].
- Net income of -$7.1M for the period ending 2026-06-30 [sec].
- Shareholders' equity of -$3.2M as of 2026-06-30 [sec].
- LP-300 Phase 2 HARMONIC trial continues enrollment in the U.S., Japan, and Taiwan; Type C meeting with FDA scheduled for mid-May 2026 [news · published 2026-03-30].
- LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, mantle cell lymphoma, and high-grade B-cell lymphomas [news · published 2026-03-30].
What works
- Multiple FDA Orphan Drug Designations for LP-284 (soft tissue sarcomas, mantle cell lymphoma, high-grade B-cell lymphomas) provide regulatory and commercial advantages [news · published 2026-03-30].
- AI platform Zeta.ai is in active demo/beta testing with over 25 biotech companies, indicating near-term commercialization potential [news · published 2026-03-30].
- FDA clearance of IND for STAR-001 (pediatric CNS cancer trial) expands pipeline into rare pediatric cancers [news · published 2026-03-30].
- USPTO Notice of Allowance for LP-284 treatment patent in aggressive B-cell lymphomas strengthens intellectual property [news · published 2026-09-22].
What to weigh
- Cash position declined from $10.1M (Dec 31, 2025) to $6.7M (Jun 30, 2026), indicating a tightening cash runway [news · published 2026-03-30] [sec].
- Negative shareholders' equity of -$3.2M as of 2026-06-30 suggests liabilities exceed assets [sec].
- Net loss of $7.1M for the six-month period ending 2026-06-30 reflects ongoing operating deficits [sec].
- All pipeline candidates are in early-to-mid-stage clinical trials (Phase 1/2 or Phase 2), with no approved products generating revenue [pipeline].
From the filings
Quoted directly from source documents.
Cash position as of December 31, 2025
“Approximately $10.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025.”
News · March 30, 2026
LP-284 Orphan Drug Designation for soft tissue sarcomas
“LP-284 receives FDA Orphan Drug Designation for soft tissue sarcomas, adding to existing designations for mantle cell lymphoma and high-grade B-cell lymphomas.”
News · March 30, 2026
FDA clears IND for STAR-001 pediatric CNS cancer trial
“FDA clears IND for planned Phase 1 pediatric CNS cancer trial of STAR-001 in Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare pediatric cancers”
News · March 30, 2026
USPTO Notice of Allowance for LP-284 patent
“the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," with claims directed to the use of the company's drug candidate LP‑284”
News · September 22, 2026
Catalyst timeline
- 2023-01-03 · Phase 1 start for LP-284 — Phase 1 dose escalation/expansion study of LP-284 in relapsed/refractory lymphomas and solid tumors began.
- 2023-03-01 · Phase 2 start for LP-300 HARMONIC trial — Phase 2 trial of LP-300 in combination with carboplatin and pemetrexed in never-smoker lung adenocarcinoma patients began.
- 2023-06-09 · Phase 1/2 start for LP-184 — Phase 1/2 dose escalation and cohort expansion study of LP-184 in advanced/metastatic solid tumors began.
Risks & what to watch (4)›
Key risks
- Cash runway — Cash declined from $10.1M (Dec 2025) to $6.7M (Jun 2026), potentially limiting operations if not replenished [news][sec].
- Negative equity — Shareholders' equity of -$3.2M as of 2026-06-30 indicates liabilities exceed assets [sec].
- No approved products — All candidates are in Phase 1/2 or Phase 2; no revenue-generating approved drugs [pipeline].
- Clinical trial execution — LP-300 HARMONIC trial is ongoing globally; delays or negative data could impact pipeline [news].
What to watch
- Outcome of FDA Type C meeting for LP-300 scheduled for mid-May 2026 [news · published 2026-03-30].
- Commercialization progress of Zeta.ai / Open-Medicine AI platform with over 25 beta testers [news · published 2026-03-30].
- Cash position updates in future quarterly filings to assess runway [sec].
- Initiation of Phase 1 pediatric CNS cancer trial for STAR-001 following IND clearance [news · published 2026-03-30].
Sources: Catalysts · News · Pipeline · Generated October 3, 2026 · How we verify sources →
Run Lantern Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lantern Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$7M
Lead: Phase 1/Phase 2
4 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$2.8M
| Holder | Shares | Value |
|---|---|---|
| bios capital management, lp | 864,435 | $1.2M |
| vanguard capital management llc | 332,079 | $455K |
| cm management, llc | 250,000 | $343K |
| renaissance technologies llc | 116,000 | $159K |
| geode capital management, llc | 111,646 | $153K |
| westside investment management, inc. | 50,050 | $69K |
| voss capital, lp | 50,000 | $69K |
| vanguard fiduciary trust co | 49,607 | $68K |
| blackrock, inc. | 45,267 | $62K |
| dimensional fund advisors lp | 38,060 | $52K |
Showing top 10 of 32 institutional holders of Lantern Pharma Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 15.5%
- Days to cover
- 1.2
- Shares short
- 1,741,042
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LTRN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lantern Pharma Inc.?
Lantern Pharma Inc. (LTRN) is a clinical-stage, AI-native biopharmaceutical company developing precision oncology therapies using artificial intelligence and genomic data, with a pipeline including Phase 2 and Phase 1/2 candidates and a wholly owned AI subsidiary.
What is Lantern Pharma Inc.'s lead drug candidate?
Lantern Pharma Inc.'s most advanced tracked candidate is lp-100 (Phase 2) for Metastatic castration resistant prostate cancer (mCRPC).
Who is the CEO of Lantern Pharma Inc.?
Mr. Panna Sharma is the chief executive officer of Lantern Pharma Inc. (LTRN).
Where is Lantern Pharma Inc. headquartered?
Lantern Pharma Inc. (LTRN) is headquartered in Dallas, TX, United States.
What therapeutic areas does Lantern Pharma Inc. focus on?
Lantern Pharma Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.